Sgd Pharma
Sgd Pharma, headquartered in France, is a leading player in the pharmaceutical packaging industry, specialising in the production of high-quality glass and plastic containers. Founded in 2002, the company has established a strong presence across Europe, Asia, and the Americas, catering to the diverse needs of the healthcare sector. With a commitment to innovation, Sgd Pharma offers a range of products, including vials, ampoules, and bottles, designed to meet stringent regulatory standards while ensuring the safety and integrity of pharmaceutical products. The company is recognised for its advanced manufacturing processes and sustainable practices, positioning it as a trusted partner for global pharmaceutical companies. Notable achievements include significant investments in technology and sustainability initiatives, reinforcing Sgd Pharma's reputation as a market leader in pharmaceutical packaging solutions.
DitchCarbon Score
How does Sgd Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Rubbe and Plastic Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sgd Pharma's score of 41 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sgd Pharma's reported carbon emissions
In 2023, SGD Pharma reported total greenhouse gas (GHG) emissions of approximately 203,584,000 kg CO2e for Scope 1 and 199,732,000 kg CO2e for Scope 2, alongside 10,000,000 kg CO2e for Scope 3 emissions. This reflects a commitment to reducing absolute Scope 1 and 2 emissions by 42% by 2030, using 2022 as the base year. Additionally, the company aims to cut Scope 3 emissions by 25% within the same timeframe. In previous years, emissions were as follows: in 2022, total emissions for Scope 1 and 2 were about 217,057,000 kg CO2e; in 2021, they were approximately 204,192,000 kg CO2e; and in 2020, they reached around 218,003,000 kg CO2e. The data indicates a general trend of emissions management, with a focus on reducing the carbon footprint associated with their operations. SGD Pharma's initiatives align with industry standards for climate action, demonstrating a proactive approach to sustainability in the containers and packaging sector. The company has not yet committed to a net-zero target but continues to engage in significant reduction efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 216,495,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 78,007,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 1,899,000 | - | - | 0,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sgd Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
